NASDAQ:HALO

Halozyme Therapeutics Earning Date

USA |NASDAQ |USD

HALO Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 1, 2021 Sep 2021 $0.42 $0.66 $0.25
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 1, 2021 Sep 2021 $106.96M $136.46M $65.32M

Halozyme Therapeutics's next earnings date is Monday, Nov 1, 2021 for the fiscal quarter ending Sep 2021.

HALO Earnings Date & History Chart

HALO Earnings & Revenue Forecast

HALO Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $0.46 $0.41 $0.54
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $1.66 $1.60 $1.73
Dec 2022 10 $2.62 $1.85 $3.00

HALO Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $0.46 $0.43 $0.43
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $1.66 $1.41 $1.41
Dec 2022 0 / 0 $2.62 $2.49 $2.49

HALO Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 9 $114.10M $102.10M $127.23M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 10 $440.70M $421.20M $467.80M
Dec 2022 12 $591.06M $465.00M $683.15M

HALO Earnings Date & Revenue History

HALO Earnings History

|
Show More
Show More

HALO Revenue History

|
Show More
Show More

Halozyme Therapeutics Next Earnings Date & Report

HALO Next Earnings Date & Report Preview: Sep 2021 (FQ)

HALO's next earnings date is Monday, Nov 1, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 9 analysts, the average EPS estimation for Halozyme Therapeutics's next quarterly earnings is $0.42, with a low EPS estimation of $0.37, and a high estimation of $0.56.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $0.42, the last 2 month trend is $0.38, and the 3 month trend is $0.38.

Based on 9 analysts, the average revenue estimation is $106.96M, with a low revenue estimation of $93.70M, and a high estimation of $122.16M.

Halozyme Therapeutics Previous Earnings Dates & Reports

HALO Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Halozyme Therapeutics's previous earnings date was Aug 9, 2021 for its fiscal quarter ended Jun 30, 2021.

HALO's earnings per share (EPS) was $0.66, beating the consensus analysts forecast of $0.44 by 51.45%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by 78.38%, and higher than the same period a year before (Jun 2020) by 247.37%.

Revenues were $136.46M, better than the forecast of $104.04M by 31.16%, up by 53.28% from the previous quarter , and up by 147.11% from the same period last year.

The company reported a net income of $91.46M, 227.87% higher than the previous quarter, and higher by 254.25% than the same period a year before.

Free cash flow for the quarter was $36.36M , compared to $58.03M last quarter and $2.78M a year before.

HALO ended the quarter with $874.74M in total debt, an increase of 0.11% compared to the previous quarter, and an increase of 36.27% compared to the same quarter a year before.

HALO Previous Earnings Date & Report Recap: Dec 2020 (FY)

Halozyme Therapeutics's previous annual earnings date was Feb 23, 2021 for its fiscal year ended Dec 31, 2020.

HALO's earnings per share (EPS) was $0.90, missing the consensus analysts forecast of $0.93 by -3.23% , and higher than the previous year's EPS (Dec 2019) by -280.00%.

Revenues were $267.59M, better than the forecast of $265.37M by 0.84%, and up by 36.53% from previous year's revenue.

The company reported a net income of $129.09M.

Halozyme Therapeutics reported a free cash flow of $52.95M for its fiscal year, compared to $-89.46M a year ago.

The company ended the fiscal year with $794.46M in total debt, an increase of 97.34% compared to the previous year.